Joel Baglole

Joel Baglole

InvestorPlace Contributor

Joel Baglole has been a financial reporter for more than 20 years. For five years, Mr. Baglole was a staff reporter at The Wall Street Journal, where he wrote articles from Iceland to Indonesia and covered topics ranging from the automotive and airline industries to investment banks and global stock markets.

Mr. Baglole has also worked for The Washington Post and Toronto Star newspapers, and has contributed to business focused websites such as The Motley Fool and Investopedia. At InvestorPlace, he covers a wide range of large and small cap stocks, as well as political and economic issues that impact financial markets.

Check out Joel’s TipRanks profile.

Recent Articles

Pinterest Stock Has a Lot More to Give Back Before It Is a Buy

By Joel Baglole, InvestorPlace Contributor

PINS stock dropped 23% immediately after the company announced its second quarter results on July 29 and the shares now trade at $58.90. Shares of Pinterest are now down 13% since the first trading day in January. While the stock was enduring ups and downs throughout the past seven months, the latest earnings appear to have dropped the floor out from underneath the company.

Hungry for Growth? Buy Facebook on the Dip

By Joel Baglole, InvestorPlace Contributor

Investors looking for a large cap growth stock that can provide steady gains should buy the current dip in social media giant Facebook. Shares of the "social network" fell 5% immediately after the company said in its latest earnings that it expects revenue growth to slow throughout the rest of this year. Investors seized on the forecast of slower growth and disregarded fact that Facebook's earnings trounced Wall Street estimates.

3 Auto Stocks to Buy as They Transition to Tech-Stock Status

By Joel Baglole, InvestorPlace Contributor

New innovations and changes in industry standards have auto stocks operating more and more like tech stocks to deliver modern experiences.

Don’t Buy Novavax Until Its Covid-19 Vaccine Wins FDA Approval

By Joel Baglole, InvestorPlace Contributor

Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days.

3 Best Space Stocks Building Critical Space Technology

By Joel Baglole, InvestorPlace Contributor

The final frontier of space is getting crowded as a growing number of companies rush to go where no man has gone before. From space tourism and research stations orbiting the moon to the colonization of Mars and an ever expanding network of satellites encircling the Earth, the space sector is red hot right now and seems to have captured the imaginations of corporate leaders and investors.

Load More